利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

805 条记录 (耗时 0.075 秒)

    PRIMARY CULTURED ADIPOCYTES FOR GENE THERAPY
    5.
    发明申请
    PRIMARY CULTURED ADIPOCYTES FOR GENE THERAPY 有权
    用于基因治疗的主要文化ADIPOCYY

    公开(公告)号：US20090010901A1

    公开(公告)日：2009-01-08

    申请号：US12175186

    申请日：2008-07-17

    申请人： Masashi Ito ,  Yasushi Saito

    发明人： Masashi Ito ,  Yasushi Saito

    IPC分类号： A61K48/00 ,  A61K35/12

    CPC分类号： C12N5/0653 ,  A61K35/12 ,  C12N2510/00 ,  C12N2510/02

    摘要： The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo gene therapy. The present invention established methods for transferring foreign genes into primary cultured adipocytes, which are suitable for ex vivo gene therapy; can be easily collected and implanted; and can be removed after implantation. Specifically, the present invention established these methods that use retroviral vectors. The present invention also established primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells.

    摘要翻译： 本发明涉及用于基因治疗的原代培养的脂肪细胞，其中脂肪细胞稳定地维持编码在细胞外分泌的蛋白质的外源基因。 本发明提供适用于基因治疗的细胞，其可代替用于常规体外基因治疗的骨髓细胞和肝细胞。 本发明建立了将外源基因转移到适合离体基因治疗的原代培养脂肪细胞中的方法; 可以轻松收集和植入; 并且可以在植入后去除。 具体地，本发明建立了使用逆转录病毒载体的这些方法。 本发明还建立了用于基因治疗的原代培养的脂肪细胞，其中脂肪细胞稳定地保持编码在细胞外分泌的蛋白质的外源基因。

    Novel Methods Using Pyridine Derivatives
    6.
    发明申请
    Novel Methods Using Pyridine Derivatives 审中-公开

    公开(公告)号：US20080234325A1

    公开(公告)日：2008-09-25

    申请号：US10311833

    申请日：2001-06-19

    申请人： John Ieni ,  Jay Barth ,  Robert M. Niecestro

    发明人： John Ieni ,  Jay Barth ,  Robert M. Niecestro

    IPC分类号： A61K31/4439 ,  A61P1/00

    CPC分类号： A61K31/4439 ,  Y02A50/411

    摘要： The invention provides methods of treating and preventing asthma, laryngitis, symptomatic gastroesophageal reflux disease, pregnancy-induced gastroesophageal reflux disease, noncardiac chest pains, coughing, apnea, dyspepsia, inflammatory bowel disease, irritable bowel syndrome, gastritis, stress ulcers, bleeding peptic ulcers, acute gastrointestinal bleeding, infectious enteritis, collagenous colitis, lymphocytic colitis, chronic diarrhea in immunocompromised patients, esophageal ulcers in immunocompromised patients, idiopathic gastric acid hypersecretion, gastroparesis, gastrointestinal motility disorders, Zollinger-Ellison syndrome, short bowel syndrome, emesis, regurgitation, early satiety, chronic sore throat, abdominal pain, abdominal bloating, nausea, sour stomach, diarrhea, constipation, bacterial infections, refractory ulcers, gastrointestinal disorders induced by NSAIDs, Barrett's esophagus, gastrointestinal disorders caused by steroids, gastrointestinal disorders induced by cholinergic compounds, and fungal or viral-induced ulcers in the gastrointestinal tract by administering a therapeutically effective amount of at least one of the pyridine derivatives of the invention to a patient in need thereof. The invention also provides on demand relief of symptoms associated with gastroesophageal reflux disease (GERD), and provides relief from symptoms caused by the consumption of excessive amounts of food and/or alcohol by administering a therapeutically effective amount of at least one of the pyridine derivatives of the invention to a patient in need thereof. The invention also provides methods for treating parasitic infections, such as malaria, by administering a therapeutically effective amount of at least one of the pyridine derivatives of the invention to a patient in need thereof. In preferred embodiments, the pyridine derivative of the invention is rabeprazole, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

    Fused indazole compounds
    7.
    发明授权
    Fused indazole compounds 失效
    稠合吲唑化合物

    公开(公告)号：US07390797B2

    公开(公告)日：2008-06-24

    申请号：US10503216

    申请日：2003-02-21

    申请人： Norihito Ohi ,  Nobuaki Sato ,  Naohiro Kohmura

    发明人： Norihito Ohi ,  Nobuaki Sato ,  Naohiro Kohmura

    IPC分类号： A61K31/416 ,  A61K31/4162 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  C07D231/54 ,  C07D245/04 ,  C07D243/10 ,  C07D225/04 ,  C07D223/14 ,  C07D267/04

    CPC分类号： A61K31/55 ,  A61K31/416 ,  A61K31/4439 ,  C07D231/54 ,  C07D401/12 ,  C07D405/12 ,  C07D487/06

    摘要： The present invention provides a novel fused indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Z11 and Z12 each independently represent a carbonyl group, a methylene group, etc.; represents a double bond or a single bond; R1a represents a hydrogen atom, etc.; the ring A represents a benzene ring, a naphthalene ring or a 5- to 10-membered aromatic heterocyclic ring, etc.; and R2a, R2b and R2c each independently represent (1) a hydrogen atom, (2) a halogen atom, (3) a nitro group, etc.

    摘要翻译： 本发明提供了具有优异JNK抑制作用的新的稠合吲唑化合物。 更具体地，它提供由下式表示的化合物，其盐或它们的水合物。 其中Z 11和Z 12各自独立地表示羰基，亚甲基等; “img id =”CUSTOM-CHARACTER-00001“he =”2.79mm“wi =”6.35mm“file =”US07390797-20080624-P00001.TIF“alt =”custom character“img-content =”character“img-format =“tif”/>表示双键或单键; R 1a表示氢原子等; 环A表示苯环，萘环或5至10元芳族杂环等; 和R 2a，R 2b和R 2c各自独立地表示（1）氢原子，（2）卤素原子，（3） 硝基等

    Novel methods using aminobenzoic acid compounds
    8.
    发明申请
    Novel methods using aminobenzoic acid compounds 审中-公开
    使用氨基苯甲酸化合物的新方法

    公开(公告)号：US20080070944A1

    公开(公告)日：2008-03-20

    申请号：US11902338

    申请日：2007-09-20

    申请人： Jay Barth ,  Kathleen Lomax ,  Scott Fields ,  Mindell Seidlin

    发明人： Jay Barth ,  Kathleen Lomax ,  Scott Fields ,  Mindell Seidlin

    IPC分类号： A61K31/439 ,  A61P3/04

    CPC分类号： A61K31/46

    摘要： The invention provides safe and effective methods for treating and/or preventing gastrointestinal disorders, psychiatric disorders, learning disabilities, Tourette's syndrome, obesity, epilepsy, post-menopausal syndrome, pre-menstrual syndrome, asthma, laryngitis and/or migraines by administering to a patient in need thereof at least one aminobenzoic acid compound. The aminobenzoic acid compound can optionally be administered in combination with other medications that are useful for the disease being treated.

    摘要翻译： 本发明提供了安全和有效的治疗和/或预防胃肠道疾病，精神病学，学习障碍，图雷特综合征，肥胖症，癫痫，绝经后综合征，月经前症状，哮喘，喉炎和/或偏头痛的方法， 需要患者的至少一种氨基苯甲酸化合物。 氨基苯甲酸化合物可任选地与可用于所治疗疾病的其它药物组合施用。